Targeting IRAK4 in Chronic Lymphocytic… | Clinical Trial

Key information

Conditions

Chronic Lymphocytic Leukemia (CLL) Chronic Disease Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC). Up to 50 ml of blood will be collected for the research project at the time of standard blood tests.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥18 years
Diagnosis of CLL
Participant is willing and able to give informed consent for participation in the study.

Exclusion criteria

Participant is unable or unwilling to provide informed consent for participation in the study

Treatment and study plan

Peripheral blood sample collection

Procedure

Up to 50 ml of blood will be collected for the research project at the time of standard blood tests.

Primary outcomes

TLR signaling

Time frame: 12 months

In vitro inhibition of TLR signaling in CLL cells following exposure to IRAK4 CDAC, as assessed by modulation of downstream signaling molecules (e.g. phosphorylation status and/or degradation of key components of the TLR pathway).

Study contacts

Contact information is provided by the study sponsor or research team.

Lydia Scarfo, MD

CONTACT

[email protected]

+390226436119

Paolo Ghia, MD, PhD

CONTACT

[email protected]

+390226434797

Sponsors and collaborators

Lead sponsor

IRCCS San Raffaele

Other

Registry information

Acronym: PS-CLL016

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Aug 3, 2026
Registry last updated: Aug 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting